Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Exsilio Therapeutics
Boston, Massachusetts, United Statesexsiliotx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Exsilio/Averna is developing a new class of redosable genomic medicines that use naturally occurring, programmable genetic elements delivered via mRNA and lipid nanoparticles. The approach aims to enable safe, efficient, scalable, and repeatable whole-gene insertions into safe harbor sites in patient genomes. The company is currently preclinical with plans to select a lead candidate using its proprietary platform.
- Therapeutic areas
- ImmunologyOncologyRare Diseases
- Modalities
- mRNA-based genomic medicinesLipid nanoparticle (LNP) delivery systemsProgrammable genetic elements for gene insertion
- Industry
- Biotech
02
Partnerships
No formal pharma partnerships announced; strong investor syndicate includes Novartis Venture Fund and CRISPR Therapeutics among others which may indicate future collaborations.
Beyond the preview
Go deeper on Exsilio Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exsilio Therapeutics.